Download - Land mark trials 2015
![Page 1: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/1.jpg)
Land mark trials in 2015
Dr K. V. Siva krishna
![Page 2: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/2.jpg)
Topic outline• Recent trials on • Hypertension • Heart failure• ACS• Lipids• PAH• Miscellaneous
![Page 3: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/3.jpg)
SPRINT trial
![Page 4: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/4.jpg)
• The SPRINT trial • A Randomized Trial of Intensive versus
Standard Blood-Pressure Control.
![Page 5: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/5.jpg)
• Among persons 50 years of age or older, isolated systolic hypertension is the most common form of hypertension, and systolic blood pressure becomes more important than diastolic blood pressure as an independent risk predictor for coronary events, stroke, heart failure, and end-stage renal disease.
![Page 6: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/6.jpg)
• Clinical trials have shown that treatment of hypertension reduces the risk of cardiovascular disease outcomes, including incident stroke (by 35 to 40%), myocardial infarction (by 15 to 25%),and heart failure (by up to 64%).
• The target for systolic blood-pressure lowering is uncertain.
![Page 7: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/7.jpg)
• The current trial Systolic Blood Pressure Intervention Trial (SPRINT), compared the benefit of treatment of systolic blood pressure to a target of less than 120 mm Hg with treatment to a target of less than 140 mm Hg.
![Page 8: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/8.jpg)
Eligibility, Randomization, and Follow-up.
The SPRINT Research Group. N Engl J Med 2015;373:2103-2116
STUDY DESIGN
![Page 9: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/9.jpg)
• PRIMARY OUTCOMES:• COMPOSITE of
myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes.
• Secondary outcomes• Included the individual
components of the primary composite outcome, death from any cause, and the composite of the primary outcome or death from any cause
• Renal outcome• With chronic kidney disease
decrease in the eGFR of 50% or more or the development of ESRD requiring long-term dialysis or kidney transplantation.
• decrease in the eGFR of 30% or more to a value of less than 60 ml per minute per 1.73 m2
![Page 10: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/10.jpg)
Characteristic Intensive Treatment(N = 4678)
Standard Treatment(N = 4683
Age ≥75 yr 1317 (28.2) 1319 (28.2)
Chronic kidney disease‡ 1330 (28.4) 1316 (28.1)
Cardiovascular disease 940 (20.1) 937 (20.0)
Female sex — no. (%) 1684 (36.0) 1648 (35.2)Systolic bp 139.7±15.8 139.7±15.4
Diastolic 78.2±11.9 78.0±12.0Statin use — no./total no. (%)
1978/4645 (42.6) 2076/4640 (44.7)
Aspirin use — no./total no. (%)
2406/4661 (51.6) 2350/4666 (50.4)
Criterion for increased cardiovascular risk — no.
Baseline Characteristics of the Study Participants.
![Page 11: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/11.jpg)
Systolic Blood Pressure in the Two Treatment Groups over the Course of the Trial.
The SPRINT Research Group. N Engl J Med 2015;373:2103-2116
![Page 12: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/12.jpg)
Primary Outcome and Death from Any Cause.
The SPRINT Research Group. N Engl J Med 2015;373:2103-2116
245
314
Total deaths 365(155 Vs 210 ) p=0.003.
155
210
P=<0.0001
![Page 13: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/13.jpg)
Forest Plot of Primary Outcome According to Subgroups.
The SPRINT Research Group. N Engl J Med 2015;373:2103-2116
![Page 14: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/14.jpg)
Primary and Secondary Outcomes and Renal Outcomes.
The SPRINT Research Group. N Engl J Med 2015;373:2103-2116
![Page 15: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/15.jpg)
Serious Adverse Events, Conditions of Interest, and Monitored Clinical Events.
The SPRINT Research Group. N Engl J Med 2015;373:2103-2116
![Page 16: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/16.jpg)
Conclusions• Conclusion: • Among patients at high risk for cardiovascular
events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.
![Page 17: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/17.jpg)
IMPROVE IT Trial
![Page 18: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/18.jpg)
Study Overview• Ezetimibe targets the Niemann–Pick C1–like 1 (NPC1L1) protein, thereby reducing absorption of cholesterol from the intestine.
• When added to statins, ezetimibe reduces LDL cholesterol levels by an additional 23 to 24%, on average.
• The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) evaluated the effect of ezetimibe combined with simvastatin, as compared with that of simvastatin alone, in stable patients who had had an acute coronary syndrome and whose LDL cholesterol values were within guideline recommendations.
• In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo
![Page 19: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/19.jpg)
• Primary end point: composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke.
• The median follow-up was 6 years
![Page 20: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/20.jpg)
STUDY PROTOCOL
![Page 21: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/21.jpg)
Baseline Characteristics.
Cannon CP et al. N Engl J Med 2015;372:2387-2397
![Page 22: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/22.jpg)
Kaplan–Meier Curves for the Primary Efficacy End Point.
Cannon CP et al. N Engl J Med 2015;372:2387-2397
![Page 23: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/23.jpg)
Plot of the IMPROVE-IT Trial Data and Statin Trials for Change in Low-Density Lipoprotein (LDL) Cholesterol versus Clinical Benefit.
Cannon CP et al. N Engl J Med 2015;372:2387-2397
![Page 24: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/24.jpg)
Primary, Secondary, and Individual End Points.
Cannon CP et al. N Engl J Med 2015;372:2387-2397
![Page 25: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/25.jpg)
Prespecified Safety End Points.
Cannon CP et al. N Engl J Med 2015;372:2387-2397
![Page 26: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/26.jpg)
Conclusions• In conclusion, the addition of ezetimibe to statin therapy
in stable patients who had had an acute coronary syndrome and who had LDL cholesterol levels within guideline recommendations further lowered the risk of cardiovascular events.
• The event reduction was consistent with the predicted effects seen with statins, even in the range of low LDL cholesterol levels in this trial, and no offsetting adverse events or toxic effects were observed.
• When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes.
• Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit.
![Page 27: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/27.jpg)
MATRIX trial
![Page 28: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/28.jpg)
• Two of the most commonly used antithrombotic worldwide are unfractionated heparin, an indirect thrombin inhibitor, with or without the concomitant use of a glycoprotein IIb/IIIa inhibitor, and bivalirudin, a direct thrombin inhibitor, with a glycoprotein IIb/IIIa inhibitor added only for periprocedural ischemic complications.
![Page 29: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/29.jpg)
Time-to-Event Curves through 30 Days
Stone GW et al. N Engl J Med 2008;358:2218-2230
HORIZONS AMI TRIAL
![Page 30: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/30.jpg)
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial
![Page 31: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/31.jpg)
Figure 2
The Lancet 2014 384, 1849-1858DOI: (10.1016/S0140-6736(14)60924-7)
Compared with bivalirudin, heparin reduces the incidence of major adverse ischaemic events in the setting of PPCI, with no increase in bleeding complications. Systematic use of heparin rather than bivalirudin would reduce drug costs substantially
![Page 32: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/32.jpg)
• MATRIX Antithrombin was a randomized comparison of bivalirudin and unfractionated heparin involving 7213 patients with ST segment elevation myocardial infarction (STEMI) or a non–ST-segment elevation acute coronary syndrome for whom PCI was planned
![Page 33: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/33.jpg)
• MATRIX Treatment Duration was a randomized comparison of prolonged bivalirudin administration with a post-PCI infusion with short-term bivalirudin administration without a post-PCI infusion,
![Page 34: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/34.jpg)
STUDY DESIGN• Total patients(7213)
Bivaluridin group(3610) Unfractionated heparin group(3603)
Post PCI infusion (1799)
No post PCI infusion (1811)
![Page 35: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/35.jpg)
• Coprimary outcomes• Major adverse cardiovascular
events,: a composite of death from anyNcause, myocardial infarction, or stroke, up to 30 days, and
• net adverse clinical events,Bleeding Academic Research Consortium [BARC] type 3 or 5 or major adverse cardiovascular events, up to 30 days.
• Primary outcome (MATRIX Treatment Duration)
• composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events up to 30 days
• Secondary outcomes • Death from cardiovascular• causes, and stent thrombosis. • Bleeding was also assessed and
adjudicated on the basis of the Thrombolysis in Myocardial Infarction (TIMI) and
• Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO17) scales.
![Page 36: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/36.jpg)
Characteristics of the Patients at Baseline.
Valgimigli M et al. N Engl J Med 2015;373:997-1009
![Page 37: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/37.jpg)
Coprimary Composite Study Outcomes at 30 Days.
Valgimigli M et al. N Engl J Med 2015;373:997-1009
![Page 38: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/38.jpg)
Primary Composite Outcome at 30 Days, According to Duration of Bivalirudin Infusion.
Valgimigli M et al. N Engl J Med 2015;373:997-1009
![Page 39: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/39.jpg)
Clinical Presentation and Medications at Baseline.
Valgimigli M et al. N Engl J Med 2015;373:997-1009
![Page 40: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/40.jpg)
Clinical Outcomes up to 30 Days.
Valgimigli M et al. N Engl J Med 2015;373:997-1009
![Page 41: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/41.jpg)
Conclusions• In patients with an acute coronary syndrome,
the rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin.
• The rate of the composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion.
![Page 42: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/42.jpg)
CONCLUSIONS• In conclusion, among patients with acute coronary
syndromes undergoing invasive treatment, neither the rate of major adverse cardiovascular events nor the rate of net adverse clinical events was significantly lower with bivalirudin than with unfractionated heparin and discretionary use of glycoprotein IIb/IIIa inhibitors.
• The post-PCI infusion of bivalirudin for at least 4 hours after the intervention did not result in a lower rate of the composite outcome of ischemic and bleeding events, including stent thrombosis, than the rate with no post-PCI infusion.
![Page 43: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/43.jpg)
AMBITION trial
![Page 44: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/44.jpg)
Background • Current therapies for pulmonary arterial hypertension
target abnormalities in one of three intracellular pathways with signaling dysfunction:
• The prostacyclin, nitric oxide, or endothelin pathway. However, no single class of drug is consistently effective in treating all patients, which suggests that no single pathway plays a dominant pathogenic role
• Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.
![Page 45: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/45.jpg)
Inclusion criteria• 18 and 75 years of age• Weight >40 kg• WHO Functional Class II or III i. mPAP of >25 mmHg ii. PVR >240 dynes.sec/cm5 iii. PCWP/LVEDP of ≤15 mmHg
Exclusion criteria• Received previous PAH therapy
(PDE5i, ERA, chronic prostanoid*) within 4 weeks prior to the Screening Visit
• Pregnant females• Inotropes with in past 2 weeks
before enrollment• Known hypersensitivity to drugs
Patient selection
![Page 46: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/46.jpg)
Follow-up (at weeks 4, 8, 16, and 24 andevery 12 weeks thereafter)
Ambrsentan+Tadalafil
Ambrsentan ALONE
End of the study
Study design
Tadalafil alone
Randomisation done in 2:1:1 ratio 0
253 patients
126 patients
121 patients
Mean follow up 610 days
Total of 500 patients
![Page 47: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/47.jpg)
End points• Components of the
Primary End Point• Death from any cause
• Hospitalization for
worsening pulmonary arterial hypertension
• Disease progression • Unsatisfactory long-term
clinical response
• Secondary end points
• Change from baseline to week 24 in N-terminal
• Pro–brain natriuretic peptide (NT-proBNP) level
• 6-minute walk distance, WHO functional class, and Borg dyspnea index
![Page 48: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/48.jpg)
Characteristic Combination-Therapy Group(N = 253
Pooled-MonotherapyGroup(N = 247
Ambrisentan-MonotherapyGroup(N = 126
Tadalafil-MonotherapyGroup(N = 121
Age 54.5±14.3 54.2±14.9
53.9±14.7 54.5±15.2
Female sex — no. (%) 188 (74) 200 (81) 100 (79) 100 (83)
Hypertension 104 (41) 95 (38) 52 (41) 43 (36)
Diabetes 19 (8) 30 (12) 13 (10) 17 (14)
Coronary artery disease
16 (6) 4 (2) 2 (2) 2 (2)
Idiopathic 127 (50) 138 (56) 72 (57) 66 (55)
Associated with connective-tissue disease
103 (41) 84 (34) 44 (35) 40 (33)
Classification of pulmonary arterial hypertension— no. (%)
Demographic and base line characteristics
![Page 49: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/49.jpg)
Disease Severity at Baseline.
Galiè N et al. N Engl J Med 2015;373:834-844
![Page 50: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/50.jpg)
Results • A total of 123 participants had a primary
endpoint event up to the time of the final-assessment visit, including 46 (18%) in the combination- therapy group and 77 (31%) in the pooled monotherapy group (43 [34%] in the ambrisentan- monotherapy group and 34 in the tadalafil-monotherapy group.
![Page 51: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/51.jpg)
Primary and Secondary Efficacy End Points.
Galiè N et al. N Engl J Med 2015;373:834-844
![Page 52: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/52.jpg)
Kaplan–Meier Curves for the Probability of a First Adjudicated Primary End-Point Event.
Galiè N et al. N Engl J Med 2015;373:834-844
![Page 53: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/53.jpg)
Safety• Peripheral edema, headache, nasal congestion
and anemia were more common in the combination- therapy group than in either monotherapy group, dizziness was more common in the combination-therapy group than in the tadalafil monotherapy group, and syncope was more common in the tadalafil-monotherapy group than in the other groups; the incidence of hypotension was similar in the three study groups.
![Page 54: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/54.jpg)
ConclusionsConclusion • Among participants with pulmonary arterial
hypertension who had not received previous treatment, the risk of the composite outcome of clinical failure was significantly lower among those who received initial combination therapy with ambrisentan and tadalafil than among those who received monotherapy with either ambrisentan or tadalafil
![Page 55: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/55.jpg)
Twelve vs 48 months of dual antiplatelet therapy after drug-eluting stent placementThe OPTIDUAL randomized trial
09/12/2015 ESC JOURNAL
![Page 56: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/56.jpg)
Background (1)The long-term risk of very late thrombosis after PCI does not decrease over time
Nearly half of the recurrent MACE after PCI for ACS are associated with non-culprit lesions at the time of PCI
Wenaweser P et al. JACC 2008;52 Stone G et al. N Engl J Med 2011;364
![Page 57: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/57.jpg)
Background (2)DAPT trial: showed a reduction in rates of MACCE and stent thrombosis but an increase in bleeding
Mauri L et al. N Engl J Med 2014;371:2155
![Page 58: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/58.jpg)
Hypothesis
• On a background of aspirin, continuing clopidogrel for up to 48 months would be superior to stopping clopidogrel at 12 months following drug-eluting stent (DES) implantation in reducing net adverse clinical events (composite of death, MI, stroke or major ISTH bleeding)– Randomized, multicentre, open-label study conducted in
58 sites in France (January 2009–January 2013)
![Page 59: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/59.jpg)
Inclusion criteria• Patients with stable
CAD or ACS• With ≥1 lesion with
a significant stenosis in an artery ≥2.25 mm
• Implanted with ≥1 DES of any type
Exclusion criteria• DES implantation in an
unprotected left main coronary artery
• Requirement for oral anticoagulation
• Malignancies or other coexisting conditions associated with a life expectancy of <2 years
Patient selection
![Page 60: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/60.jpg)
DES insertion
12 ± 3 monthsASPIRIN + CLOPIDOGREL
Randomization of patients free of MACCE or
bleed
Follow-up (every 6 months between 12 and 48 months)
ASPIRIN + CLOPIDOGREL
ASPIRIN ALONE
End of the study
0 12 months 48 months
Study design
![Page 61: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/61.jpg)
Methods• Primary endpoint
– Net adverse clinical events: composite of all-cause death, non-fatal MI, stroke, or major bleeding (ISTH classification)
• Secondary endpoints– Individual components of the primary outcome – Stent thrombosis (defined according to the
Academic Research Consortium [ARC])– Repeat revascularization of the treated vessel – Bleeding (ISTH, GUSTO, TIMI, BARC
classifications)
![Page 62: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/62.jpg)
Superiority trial: – 983 patients per arm – 80% power, alpha type-I error of 5%– Significant reduction in the primary composite
outcome at 3 years post-randomization from 7% with aspirin alone to 4% with extended DAPT
Owing to lack of resources and slower enrolment than anticipated, the executive committee and sponsor recommended termination of follow-up at the end of September 2014
Statistical analysis
![Page 63: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/63.jpg)
Patient flow chart (CONSORT)
![Page 64: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/64.jpg)
EXTENDED DAPT GROUPn=695
ASPIRIN GROUPn=690
P value
Age (years), mean (SD) 64.1 (10.8) 64.2 (11.5) 0.88
Women 18.3% 20.7% 0.23
Diabetes mellitus 30.6% 32.2% 0.54
Hypertension 57% 60.4% 0.19
Current/recent smoker 61.2% 57.8% 0.21
Previous PCI 25.9% 27.0% 0.66
Previous MI 17.1% 17.7% 0.78Previous CABG 5.3% 5.1% 0.83
Stroke or TIA 4.2% 3.6% 0.60
Peripheral artery disease
4.9% 6.5% 0.19
Patient baseline characteristics
![Page 65: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/65.jpg)
EXTENDED DAPT GROUP n=695 ASPIRIN GROUP n=690 P value
Indication for PCI
STEMI 10.7% 11.9% 0.47
Non-STEMI 14.2% 17.0% 0.39
Unstable angina 9.5% 9.1% 0.81
Stable angina 34.5% 30.0% 0.07
Silent ischaemia 19.9% 21.9% 0.35
Other 11.2% 10.1% 0.63
Type of DES
Sirolimus 19.9% 17.5% 0.17
Paclitaxel 15.2% 16.0% 0.65
Zotarolimus 8.3% 10.8% 0.05
Everolimus 50.2% 49.2% 0.66
Other 6.4% 6. 5% 0.93
Target vessel
Left main <1% >1% 0.69
LAD 58% 64% 0.007
LCX 33% 31% 0.59
RCA 41% 39% 0.58
Procedural characteristics
65.6%
34.4% 38.0%
62.0%
35.1% 33.5%
![Page 66: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/66.jpg)
EXTENDED DAPT GROUP n=695
ASPIRIN GROUP n=690
P value
Statin 94.4% 93.3% 0.41
ACE inhibitor 75.1% 74.2% 0.71
Proton-pump inhibitor 49.8% 46.8% 0.27
Beta-blocker 78.0% 81.6% 0.09
Calcium-channel inhibitor
30.9% 29.0% 0.43
Aspirin 100% 99.6% 0.12
Daily dose of aspirin at the time of randomization (mg)
0.84
≤100 78.6% 78.2%
101–300 21.4% 21.8%
Treatment at randomization
![Page 67: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/67.jpg)
R 0.75, 95% CI 0.50-1.28P=0.17
5.8%
7.5%
Primary outcome:Composite of death, MI, stroke, major bleed
![Page 68: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/68.jpg)
Components of the primary endpoint
HR 0.65, CI 0.34-1.22 P=0.18
HR 0.69, CI 0.22-2.18 P=0.53
HR 0.67, CI 0.31-1.44 P=0.31
HR 0.98, CI 0.47-2.05 P=0.95
Death Stroke
MI Major bleed
![Page 69: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/69.jpg)
4.2%
6.4%
HR 0.64, 95% CI 0.40-1.02P=0.06
Post-hoc analysis of ischaemic outcomes: death, stroke, or MI
![Page 70: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/70.jpg)
Bleeding eventsExtended-DAPT
groupAspirin group Difference
Percentage points (95% CI)
P value
GUSTO moderate or severe
1.9% 1.7% 0.1 (-1.3 to 1.5) 0.85
Moderate 1.6% 1.2% 0.4 (-0.8 to 1.7) 0.49
Severe 0.4% 0.6% -0.2 (-0.9 to 0.6) 0.72
BARC type 2.6% 2.9% - 0.3 (-2.0 to 1.4) 0.72
2 0.7% 1.0% -0.3 (-1.3 to 0.7) 0.85
3 1.9% 2.0% -0.1 (-1.6 to 1.3) 0.83
5 0.1% 0 0.1 (-0.1 to 0.4) 1.00
TIMI major or minor 2.6% 2.9% -0.3 (-1.4 to 2.0) 0.72
Major 0.6% 0.6% 0.0 (-0.8 to 0.8) 1.00
Minor 2.2% 2.3% -0.1 (-1.7 to 1.4) 0.84
ISTH major 2.0% 2.0% 0.0 (-1.5 to 1.5) 0.98
ISTH moderate 0.9% 1.0% -0.1 (-1.1 to 0.9) 0.77
![Page 71: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/71.jpg)
Meta-analysis of RCTs testing 12 months vs longer DAPT after
DES: Death, stroke, MI
![Page 72: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/72.jpg)
Meta-analysis of RCTs testing 12 months vs longer DAPT after
DES: Death, stroke, MI
![Page 73: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/73.jpg)
Study limitations
• Only powered to detect major differences in ischaemic and bleeding events
• Termination of the trial before enrolment and follow-up were completed reduced the trial power
• Open-label trial, although all clinical outcomes were adjudicated by an independent clinical event committee blinded to treatment assignment
![Page 74: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/74.jpg)
Conclusions (1)
Extending DAPT duration for up to 48 months
did not achieve statistical superiority
compared with stopping clopidogrel at 12
months with regards to net adverse clinical
outcomes, in patients free of MACCE and
major bleed 12 months after stent implantation
![Page 75: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/75.jpg)
Conclusions (2) • Borderline but non-statistically significant
reduction in post-hoc analysis of
ischaemic outcomes with extended DAPT
• No apparent increase in bleeding and all-
cause mortality with extended DAPT
![Page 76: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/76.jpg)
TOTAL TRIAL
![Page 77: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/77.jpg)
BACKGROUND
TAPAS TRIAL
![Page 78: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/78.jpg)
Results from TASTE(september 18, 2014)
NEJM
Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year
![Page 79: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/79.jpg)
INCLUSION CRITERIA• Patients with
STEMI who were referred for primary PCI within 12 hours after the onset of symptoms were eligible to participate in the trial.
EXCLUSION CRITERIA• Patients who had
undergone previous coronaryartery bypass grafting or those who had received fibrinolytic therapy were not eligible
TOTAL TRIAL
![Page 80: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/80.jpg)
Follow-up
THROMBECTOMY+ PCI
End of the study
Study design
PCI ALONE
Randomisation done in 1:1 ratio 0
Mean follow up 180 days Total of 10,732 patients
5372 patients
5360 PATIENTS
![Page 81: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/81.jpg)
![Page 82: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/82.jpg)
• Primary outcome • composite of death from
cardiovascular causes, recurrent myocardial infarction, cardiogenic shock, or New York Heart Association (NYHA) class IV heart failure within 180 days. The key
• Safety outcome was stroke within 30 days
![Page 83: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/83.jpg)
![Page 84: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/84.jpg)
![Page 85: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/85.jpg)
![Page 86: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/86.jpg)
LIMITATIONS• First: The treating interventional cardiologists
were aware of study group assignments. (BIAS)• Second: study included pt with less thrombus
burden also• Third: This trial evaluated a strategy of routine
upfront thrombectomy versus PCI alone with thrombectomy reserved as bailout; it did not study the effect of selective use of thrombectomy versus no thrombectomy
![Page 87: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/87.jpg)
• Conclusion:• In patients with STEMI who were undergoing PCI, a
strategy of routine manual thrombectomy did not reduce the risk of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or class IV heart failure within 180 days, as compared with a strategy of PCI alone with only bailout thrombectomy.
• Routine thrombectomy was associated with an increased rate of stroke within 30 days.
![Page 88: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/88.jpg)
![Page 89: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/89.jpg)
• The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established
![Page 90: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/90.jpg)
Inclusion criteria• Men and women >50 years • Documented history of presumed
spontaneous MI with their most recent MI occurring 1 to 3 years prior to randomization and have at least 1 of the following risk factors: − Age ≥65 years
• − Diabetes mellitus requiring medication
• −Documented history of a second prior presumed spontaneous MI (>1 year ago)
• − Angiographic evidence of multivessel coronary artery disease (CAD)
• Chronic, non-end stage renal ds• Able to take ASA 75-150 mg/d
Exclusion criteria• Planned use of ADP receptor
blockers • Planned coronary,
cerebrovascular, or peripheral arterial revascularization
• Need for chronic oral anticoagulant therapy or chronic LMWH
• Ischemic stroke <14 days• Liver and renal failure on HD• Pregnancy/lactation• Life expectancy <1 yr• CABG in last 5 yr• h/o IC bleed or major Sx <30 day
or GI bleed <6 mnths
Patient selection
![Page 91: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/91.jpg)
Primary outcomes• Composite of
cardiovascular death, myocardial infarction, or
• Stroke . Secondary outcomes• Cardiovascular death
and • Death from any cause
• Primary safety end point • Thrombolysis in
Myocardial Infarction (TIMI) major bleeding
• Secondary safety endpoint
• Intracranial hemorrhage• Fatal bleeding
![Page 92: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/92.jpg)
Protocol Randomised in 1:1:1 fashion
![Page 93: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/93.jpg)
Kaplan–Meier Rates of Cardiovascular Death, Myocardial Infarction, and Stroke through 3 Years, According to Study Group.
Bonaca MP et al. N Engl J Med 2015;372:1791-1800
![Page 94: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/94.jpg)
Hazard Ratios and Rates of the Primary End Point and Individual Components for Each Dose of Ticagrelor and for the Two Doses Pooled.
Bonaca MP et al. N Engl J Med 2015;372:1791-1800
![Page 95: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/95.jpg)
Safety End Points as 3-Year Kaplan–Meier Estimates.
Bonaca MP et al. N Engl J Med 2015;372:1791-1800
![Page 96: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/96.jpg)
Conclusions • The rates of bleeding and dyspnea were numerically
lower with the 60-mg dose of ticagrelor than with the 90-mg dose, resulting in a lower rate of discontinuation of the study drug and a better safety profile with the 60-mg dose.
• Thus, in general, the 60-mg dose may offer a more attractive benefit–risk profile, although these differences were not significant
![Page 97: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/97.jpg)
• In conclusion, the addition of ticagrelor, at a dose of 90 mg twice daily or 60 mg twice daily, to low-dose aspirin reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased in the risk of TIMI major bleeding among patients who had had a myocardial infarction 1 to 3 years earlier.
![Page 98: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/98.jpg)
![Page 99: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/99.jpg)
• Background• Dual antiplatelet therapy is recommended
after coronary stenting to prevent thrombotic
• complications, yet the benefits and risks of treatment beyond 1 year are uncertain.
![Page 100: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/100.jpg)
• Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin.
![Page 101: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/101.jpg)
![Page 102: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/102.jpg)
End points • The coprimary
efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months.
• The primary safety end point was moderate or severe bleeding
![Page 103: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/103.jpg)
![Page 104: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/104.jpg)
![Page 105: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/105.jpg)
• Conclusions• Dual antiplatelet therapy beyond 1 year
after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
![Page 106: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/106.jpg)
Land mark trails of 2014
Valsartan/sacubitril (codenamed LCZ696) is an investigational combination drug consisting of two antihypertensives in a 1:1 mixture by molecule count
![Page 107: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/107.jpg)
Eligibility requirements an age of at least 18 years, • (NYHA) class II, III, or IV
symptoms, EF< 40% • BNP level of at least 150 pg/ml
(OR [NT-proBNP] level ≥600 pg/ml)or, if they had been hospitalized for heart failure within the previous 12 months, a BNP of at least 100 pg/ml (or an NT-proBNP≥400 pg/ml).
• Patients taking any dose of an ACE inhibitor or ARB were considered for participation, but for at least 4 weeks before screening, patients were required to take a stable dose of a beta-blocker and an ACE inhibitor (or ARB) equivalent to at least 10 mg of enalapril daily.
Exclusion criteria • Symptomatic hypotensionSBP 100
mm Hg at screening or 95 mm Hg at randomization,
• eGFR below 30 ml/min/1.73 of BSA at screening or at randomization or a decrease in the eGFR of more than 25% (which was amended to 35%) between screening and randomization,
• a serum potassium level of more than 5.2 mmol/lat screening (or above 5.4 mmol per liter at randomization),
• history of angioedema or unacceptable side effects during receipt of ACE inhibitors or ARBs
![Page 108: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/108.jpg)
Land mark trails of 2014
![Page 109: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/109.jpg)
conclusion• In, angiotensin receptor–neprilysin inhibition with
LCZ696 was superior to ACE inhibition alone in reducing the risks of death and of hospitalization for heart failure.
• The magnitude of the beneficial effect of LCZ696, as compared with enalapril, on cardiovascular mortality was at least as large as that of long-term treatment with enalapril, as compared with placebo.
• This robust finding provides strong evidence that combined inhibition of the angiotensin receptor and neprilysin is superior to inhibition of the renin–angiotensin system alone in patients with chronic heart failure.
![Page 110: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/110.jpg)
Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan
• To estimate the long-term treatment effects of sacubitril– valsartan versus enalapril, they derived actuarial estimates of age-specific event rates and expected survival times using data regarding the age at randomization and the age at the time of an outcome event from the PARADIGM-HF trial.
![Page 111: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/111.jpg)
Claggett B et al. N Engl J Med 2015;373:2289-2290.
Probability of Death from Any Cause or the Primary End Point Extrapolated from the PARADIGM-HF Trial, According to Age Group.
![Page 112: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/112.jpg)
• The protective effects of sacubitril–valsartan remain consistent with long-term use, the available follow up data estimate that treatment with sacubitril–valsartan would result in a projected benefit of 1 to 2 years of increased life expectancy and survival free from heart failure for patients such as those in the PARADIGM-HF trial.
![Page 113: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/113.jpg)
![Page 114: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/114.jpg)
• Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin– kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies.
![Page 115: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/115.jpg)
![Page 116: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/116.jpg)
Follow-up
Evalocumab group
End of the studyStudy design
Standard therapy
Randomisation done in 2:1 ratio 0 Mean follow up
11.1 months.
Total of 4465 patients
2976 patients
1489 PATIENTS
Evalocumab 420mg s/c once in a month
Evalocumab 140mg s/c every 2 weeks or 420mg /month
![Page 117: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/117.jpg)
![Page 118: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/118.jpg)
![Page 119: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/119.jpg)
![Page 120: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/120.jpg)
• In conclusion, patients who had previously participated in 12 shorter-term parent trials of the PCSK9 inhibitor evolocumab underwent repeat randomization to receive either evolocumab or standard therapy in the OSLER program.
• Evolucumab reduced levels of LDL cholesterol by 61% by 12 weeks, with sustained reduction through the median 11-month follow- up.
• In a prespecified exploratory analysis, there was evidence of a reduction in the rate of cardiovascular events among patients receiving evolocumab
![Page 121: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/121.jpg)
![Page 122: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/122.jpg)
![Page 123: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/123.jpg)
![Page 124: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/124.jpg)
• Clinical Inclusion Criteria:• Patient must have a diagnosis
of diabetes mellitus (Type 1 or Type 2) defined according to the American Diabetes Association
• Symptomatic coronary artery disease.
• Angiographic Inclusion Criteria:
• Lesions 34 mm or less in length and a reference-vessel diameter between 2.25 mm and 4.0 mm
• Clinical Exclusion Criteria• LVEF <30%• Acute or chronic Kidney
disease• Serious medical illness with ife
expectancy <12 mnths• Angiographic Exclusion
Criteria:• LMCA stenting• Venous graft stenting• Bifurcation stenting• ISR
![Page 125: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/125.jpg)
• Primary end point • Target-vessel failure was
defined as a• composite of cardiac
death, • target-vessel myocardial
infarction, or • ischemia-driven target-
vessel revascularization
• Secondary end points• ischemia-driven target-
lesion revascularization,• target-vessel
revascularization, the composite of cardiac death or target-vessel myocardial infarction, major adverse cardiac events.
![Page 126: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/126.jpg)
![Page 127: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/127.jpg)
Clinical Outcomes.
Kaul U et al. N Engl J Med 2015;373:1709-1719
![Page 128: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/128.jpg)
Prespecified Subgroup Analyses of the Primary End Point.
Kaul U et al. N Engl J Med 2015;373:1709-1719
![Page 129: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/129.jpg)
Conclusion • Study did not show noninferiority of paclitaxel-
eluting stents to everolimus eluting stents in patients with coronary artery disease and diabetes mellitus. Everolimus-eluting stents were superior to paclitaxel-eluting stents with regard to several end points, including target-vessel failure, myocardial infarction, and stent thrombosis.
![Page 130: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/130.jpg)
A noniferiority trial
![Page 131: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/131.jpg)
• Inclusion criteria• 18 years of age or older with
myocardial ischemia who were undergoing PCI for one or two new native coronary artery lesions in separate epicardial coronary vessels were eligible for enrollment.
• Each lesion was required to be no more than 24 mm in length with a reference-vessel diameter of 2.5 to 3.75 mm on visual assessment.
• Exclusion criteria• Patients with acute
myocardial infarction and specific complex lesion features were excluded
![Page 132: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/132.jpg)
![Page 133: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/133.jpg)
• The primary end point was target-lesion failure (a composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization) at 1 year.
• Secondary end points were the 1-year rates of angina (excluding symptoms through the time of hospital discharge), all revascularization, and ischemia-driven target-vessel revascularization
![Page 134: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/134.jpg)
Target-Lesion Failure at 1 Year.
Ellis SG et al. N Engl J Med 2015;373:1905-1915
![Page 135: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/135.jpg)
Subgroup Analyses of Target-Lesion Failure at 1 Year.
Ellis SG et al. N Engl J Med 2015;373:1905-1915
![Page 136: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/136.jpg)
• The Absorb everolimus-eluting bioresorbable vascular scaffold was within the prespecified noninferiority margin in comparison with the Xience everolimus-eluting cobalt–chromium stent for the primary end point of target lesion failure at 1 year.
• Although 1-year thrombosis rates were not significantly different between the Absorb scaffold and the Xience stent, subacute thrombosis between 1 day and 30 days was more common with the Absorb scaffold in the intention-to-treat analysis
![Page 137: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/137.jpg)
Conclusion • In conclusion, in this large-scale
randomized trial, treatment of noncomplex coronary lesions with the Absorb everolimus-eluting bioresorbable vascular scaffold was within the prespecified range for noninferiority to the Xience everolimus-eluting cobalt–chromium stent with regard to target-lesion failure at 1 year.
![Page 138: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/138.jpg)
An observational study
From New York University School of Medicine,New York (S. Bangalore, Y.G., S.Blecker, J.X.); and the School of PublicHealth, State University of New York atAlbany, Albany (Z.S., E.L.H.). Address reprintrequests to Dr. Bangalore at the CardiovascularClinical Research Center, NewYork University School of Medicine, NewYork, NY 10016, or at [email protected] article was published on March 16,2015, at NEJM.org.
![Page 139: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/139.jpg)
![Page 140: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/140.jpg)
![Page 141: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/141.jpg)
• Selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.
![Page 142: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/142.jpg)
Inclusion criteria• The study population included patients 18 to 75 years of age who
had idiopathic or heritable pulmonary arterial hypertension or pulmonary arterial hypertension associated with human immunodeficiency virus infection, drug use or toxin exposure, connective tissue disease, or repaired congenital systemic-to-pulmonary shunts.
• Confirmation of the diagnosis by means of right heart catheterization was required before screening.
• Patients were required to have a pulmonary vascular resistance of at least 5 Wood units (400 dyn · sec · cm−5) and a 6-minute walk distance of 50 to 450 m.
• Patients who were not receiving treatment for pulmonary arterial hypertension and those who were receiving an endothelin- receptor antagonist, a phosphodiesterase type 5 inhibitor, or both at a dose that had been stable for at least 3 months were eligible for enrollment.
![Page 143: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/143.jpg)
• Patients who were receiving prostacyclin analogues were not eligible.
![Page 144: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/144.jpg)
Enrollment, Randomization, and Follow-up.
Sitbon O et al. N Engl J Med 2015;373:2522-2533
![Page 145: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/145.jpg)
• Primary endpoint• Composite of death or • PAH complications that
include 1. Disease progression 2. worsening PAH, req
hospitalisation3. Initiation of parenteral
prostanoid therapy or4. long-term oxygen
therapy, or 5. Need for lung
transplantation or BAS.
• Secondary end points• in 6-minute walk
distance from baseline to week 26.
• worsening NYHA class• death due to PAH or• Hospitalization due to
PAH worsening • death from any cause up
to the end of the study
![Page 146: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/146.jpg)
Primary Composite End Point.
![Page 147: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/147.jpg)
End Points Related to Pulmonary Arterial Hypertension and Death.
Sitbon O et al. N Engl J Med 2015;373:2522-2533
![Page 148: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/148.jpg)
Most Frequent Adverse Events and Abnormal Laboratory Results.
Sitbon O et al. N Engl J Med 2015;373:2522-2533
![Page 149: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/149.jpg)
• In conclusion, among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower among patients who received selexipag than among those who received placebo.
• There was no significant difference in mortality between the two study groups.
![Page 150: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/150.jpg)
ANNEXA-A and ANNEXA-R
![Page 151: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/151.jpg)
• Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs.
• Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors.
![Page 152: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/152.jpg)
![Page 153: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/153.jpg)
![Page 154: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/154.jpg)
![Page 155: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/155.jpg)
ANNEXA-A and ANNEXA-Rland mark trials in 2015
![Page 156: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/156.jpg)
• Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs.
• Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors.
land mark trials in 2015
![Page 157: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/157.jpg)
land mark trials in 2015
![Page 158: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/158.jpg)
Take home message 1. Intensive blood pressure control resulted in
lower rates of fatal and nonfatal major cardiovascular events and death from any cause.
2. When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes.
3. The use of evolocumab or arilocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events
land mark trials in 2015
![Page 159: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/159.jpg)
• The rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin.
• Routine manual thrombectomy, as compared with PCI alone, did not reduce the risk of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA class IV heart failure within 180 days.
land mark trials in 2015
![Page 160: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/160.jpg)
• Everolimus-eluting stents were superior to paclitaxel-eluting stents with regard to several end points, including target-vessel failure, myocardial infarction, and stent thrombosis.
• The addition of ticagrelor, at a dose of 90 mg twice daily or 60 mg twice daily, to low-dose aspirin reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased in the risk of TIMI major bleedingland mark trials in 2015
![Page 161: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/161.jpg)
• The addition of ticagrelor, at a dose of 90 mg twice daily or 60 mg twice daily, to low-dose aspirin reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased in the risk of TIMI major bleeding among patients who had had a myocardial infarction 1 to 3 years earlier.
• The protective effects of sacubitril–valsartan remain consistent with long-term use, the available follow up data estimate that treatment with sacubitril–valsartan would result in a projected benefit of 1 to 2 years of increased life expectancy and survival free from heart failure for patients such as those in the PARADIGM-HF trial.
land mark trials in 2015
![Page 162: Land mark trials 2015](https://reader035.vdocument.in/reader035/viewer/2022070601/5887255d1a28abfb0b8b661b/html5/thumbnails/162.jpg)
•Thank you
land mark trials in 2015